Strides Pharma SCI Ltd
NSE: STAR · Pharmaceuticals · sector
₹1,033.10NSE close 2026-10-26
Key numbers
Market cap₹9,522 cr
Price₹1,033.10
52w high / low₹1,261 / ₹769
P/E15.5xSector median 27.9x
P/B3.1xSector median 2.9x
Book value₹337.1
Dividend yield0.39%Sector median 0.48%
ROE21.7%Sector median 11.7%
ROCE19.2%Sector median 12.3%
OPM19.6%Sector median 14.0%
Debt / equity0.54xSector median 0.16x
EV/EBITDA11.2xSector median 18.6x
Interest cover5.3x
Current ratio1.25x
Sales growth 3y+9.6%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.23x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹213 cr vs borrowings ₹1,669 cr (FY26): borrowings are higher by ₹1,456 cr.
- Borrowings fell in each of the last 3 years (₹2,774 cr → ₹1,669 cr).
- Operating profit covered interest 5.3x in the last 12 months.
- 33.79% of the promoters' shares are pledged (9.8% of all shares).
- Promoter holding rose by 1.14 percentage points in a year, to 29.00% (2026-09-30).
- Operating cash flow was below net profit in 1 of the last 5 years (FY25).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 24% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹1,033.10 on 2026-10-26: -18.1% from the 52-week high, +34.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,595.35 · low ₹584.40
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,201 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| EBITDA | 232 | 208 | 190 | 210 | 223 | 233 | 233 | 293 |
| OPM % | 19.3% | 18.0% | 16.0% | 18.7% | 18.2% | 19.5% | 17.6% | 23.2% |
| Other income | 28 | 6 | 12 | 9 | 27 | 107 | 8 | 5 |
| Net profit | 93 | 88 | 82 | 100 | 128 | 202 | 127 | 157 |
| EPS (₹) | 10.14 | 9.56 | 8.92 | 10.81 | 13.84 | 21.93 | 13.77 | 17.02 |
| Revenue YoY | +1.6% | +3.6% | +11.2% | +13.0% | ||||
| Profit YoY | +36.8% | +129.8% | +54.4% | +57.5% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3,070 | 3,688 | 4,051 | 4,565 | 4,859 | 5,004 |
| EBITDA | -264 | 413 | 554 | 867 | 898 | 982 |
| Net profit | -460 | -203 | -71 | 3,593 | 556 | 614 |
| EPS (₹) | -51.28 | -22.49 | -7.76 | 390.54 | 60.34 | 66.56 |
| Revenue growth | +20.1% | +9.8% | +12.7% | +6.4% | +7.3% | |
| Profit growth | – | – | – | -84.5% | +69.0% | |
| Dividend / share (₹) | 2.50 | – | 1.50 | 2.50 | 4.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +9.6% | +7.9% | +7.3% |
| Net profit | – | +15.7% | +69.0% |
| EPS | – | +15.0% | – |
| Share price | – | -20.9% (2y) | +26.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 2,212 | 2,126 | 2,552 | 3,108 |
| Borrowings | – | 2,774 | 2,415 | 1,796 | 1,669 |
| Cash & equivalents | – | 367 | 297 | 206 | 213 |
| Total assets | – | 6,638 | 5,840 | 6,049 | 6,927 |
| Fixed assets | – | 1,324 | 879 | 881 | 992 |
| Capital work in progress | – | 48 | 80 | 100 | 161 |
| Investments | – | 53 | 8 | 329 | 279 |
| Receivables | – | 1,299 | 1,142 | 1,203 | 1,289 |
| Inventory | – | 1,147 | 1,126 | 1,278 | 1,635 |
| Payables | – | 982 | 852 | 1,032 | 1,310 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -258 | 44 | 701 | 684 | 703 |
| Cash from investing | -119 | 302 | -150 | -90 | -173 |
| Cash from financing | 421 | -214 | -693 | -643 | -453 |
| Capex | 143 | 95 | 118 | 242 | 423 |
| Free cash flow | -401 | -51 | 583 | 442 | 280 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -9.2% | -3.3% | 140.8% | 17.9% |
| ROCE % | – | 5.2% | 8.2% | 16.9% | 17.7% |
| Debtor days | – | 129 | 103 | 96 | 97 |
| Inventory days | – | 257 | 251 | 236 | 305 |
| Payable days | – | 220 | 189 | 190 | 244 |
| Cash conversion cycle (days) | – | 166 | 165 | 142 | 158 |
| Working capital days | – | 14 | 8 | 41 | 54 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 29.00% |
| FIIs | 27.98% |
| DIIs | 15.51% |
| of which Mutual funds | 10.31% |
| of which Insurance | 3.55% |
| Government | 0.01% |
| Public (non-institutions) | 27.51% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 26.82% | 28.30% | 28.30% | 27.86% | 27.86% | 27.91% | 27.91% | 29.00% |
| Promoter group | % |
|---|---|
| Pronomz Ventures LLP | 19.62% |
| Karuna Business Solutions LLP | 3.50% |
| Arun Kumar Pillai | 3.10% |
| K R Ravishankar | 1.36% |
| Agraganya Private Trust (Trustee: Barclay Wealth Trustees (I) PVT Ltd) | 0.33% |
| Karuna Family Private Trust (Trustee: Barclay Wealth Trustees (I) PVT Ltd) | 0.23% |
| Vineetha Mohanakumar Pillai | 0.21% |
| Padmakumar Karunakaran Pillai | 0.20% |
| K R Lakshmi | 0.14% |
| Sajitha Pillai | 0.10% |
| Rajitha Gopalakrishnan | 0.07% |
| Hemalatha Pillai | 0.07% |
| Aditya Arun Kumar | 0.06% |
| Anuradha K R | 0.01% |
| Deepa Arun Kumar | 0.00% |
| Public holders above 1% | % |
|---|---|
| Quant Mutual Fund - Quant Multi CAP Fund | 6.18% |
| Route ONE Offshore Master Fund, L.P. | 5.05% |
| SBI Life Insurance Co. Ltd | 3.47% |
| Bandhan BSE Healthcare Index Fund | 2.79% |
| Route ONE Fund I, L.P. | 2.17% |
| Satpal Khattar | 1.60% |
| ABU Dhabi Investment Authority - Monsoon | 1.46% |
| Authum Investment and Infrastructure Limited | 1.34% |
| Mukul Mahavir Agrawal | 1.12% |
| Oman India Joint Investment Fund II | 1.10% |
| Ishares Core Msci Emerging Markets ETF | 1.02% |
| Vanguard Total International Stock Index Fund | 1.01% |
93,336 shareholders. Pledged: 33.79% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| STAR | ₹9,522 cr | 15.5x | 3.1x | 21.7% | 19.2% | 19.6% | +9.6% | 0.39% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-31 | Dividend | Dividend - Rs 5 Per Share |
| 2025-07-22 | Dividend | Dividend - Rs 4 Per Share |
| 2024-12-06 | Restructuring | Demerger |
| 2024-09-09 | Dividend | Dividend - Rs 2.50 Per Share |
| 2023-08-04 | Dividend | Dividend - Rs 1.50 Per Share |
| 2021-08-05 | Dividend | Dividend - Rs 2.50 Per Share |
| 2020-07-24 | Dividend | Annual General Meeting/Dividend - Rs 2 Per Share |
| 2019-08-22 | Dividend | Interim Dividend - Rs 12 Per Share |
| 2019-07-19 | Dividend | Annual General Meeting/Dividend - Rs 3 Per Share |
| 2018-09-12 | Dividend | Annual General Meeting/Dividend Rs 2 Per Share |
| 2018-04-06 | Restructuring | Scheme Of Arrangement |
| 2017-09-07 | Dividend | Annual General Meeting/Dividend - Rs 4.50 Per Share |
| 2016-07-21 | Dividend | Annual General Meeting/ Dividend - Rs 4/- Per Share |
| 2015-07-22 | Dividend | Annual General Meeting/ Dividend - Rs 3/- Per Share |
| 2014-10-16 | Dividend | Special Dividend Rs.105/- Per Share |
| 2014-09-01 | Dividend | Annual General Meeting / Dividend - Rs 5/- Per Share |
| 2013-12-19 | Dividend | Special Dividend - Rs 500/- Per Share |
| 2013-05-30 | Dividend | Annual General Meeting And Dividend Rs.2/- Per Share |
| 2012-05-14 | Dividend | Annual General Meeting And Dividend Rs.2/- Per Share |
| 2011-05-18 | Dividend | Annual General Meeting And Dividend Rs.1.50 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Chemical and chemical products, pharmaceuticals, medicinal chemical, and botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | STAR |
| BSE code | 532531 |
| ISIN | INE939A01011 |
| Face value | ₹10.0 |
| Incorporated | 1990-06-28 |
| Website | www.strides.com |
| Plants (India / abroad) | 5 / 3 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.